Clinical research of different neo-adjuvant chemotherapy for the preoperative patients with advanced gastric cancer
10.3969/j.issn.1671-8348.2013.30.015
- VernacularTitle:王洪云1，黄忠英2，赵艳萍2，张文婷3，曹继红4
- Author:
Hongyun WANG
;
Zhongying HUANG
;
Yanping ZHAO
;
Wenting ZHANG
;
Jihong CAO
- Publication Type:Journal Article
- Keywords:
chemotherapy,adjuvant;
stomach neoplasms;
survival rate;
postoperative complications;
radical mastectomy
- From:
Chongqing Medicine
2013;(30):3628-3630
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the recent clinical effects and toxicity in advanced gastric carcinoma by neo-adjuvant chemo-therapy FOLFOX and XELOX .Methods A total of 81 patients with Ⅱ ~ Ⅲ level of gastric cancer underwent neo-adjuvant chemo-therapy before curative resection were collected ,and divided into two groups ,as XELOX group(n=26) and FOLFOX group(n=25) .30 patients who just underwent surgical treatment did not received neo-adjuvant chemotherapy were taken into control group(n=30) .The curative resection rate and complications were compared in three groups .Results There were no obvious differences be-tween XELOX group and FOLFOX group in recent clinical effect (P>0 .05) ,but FOLFOX group had higher toxic reaction rate (P<0 .05) .The curative resection rates of XELOX group and FOLFOX group were higher than that of control group (P<0 .05) . The complication rates in three groups showed no significant difference (P>0 .05) .Conclusion Neo-adjuvant chemotherapy could increase the curative resection rate of advanced gastric cancer ,which does not increase the complications ,and the program XELOX had less toxic reaction .
